Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Melanoma 2Head and Neck Neoplasms 2Uveal Melanoma 1Urogenital Neoplasms 1Thymoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcopenia 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Gliosarcoma 1Glioblastoma 1Genital Neoplasms, Female 1Endometrial Neoplasms 1Efficacy, Team 1Carcinoma, Ovarian Epithelial 1Advanced Solid Tumours 1Advanced Solid Tumor 1Adrenocortical Carcinoma 1

Interventions

pembrolizumab 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Neoplasms, Glandular and Epithelial × pembrolizumab × Clear all
NCT04519151 2023-06-08

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Sheba Medical Center

Phase 2 Recruiting
24 enrolled
GastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Stomach Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡